Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
18.64(c) 18.8(c) 19.66(c) 20.73(c) 19.5(c) Last
1 009 259 985 035 1 279 509 1 536 868 2 138 015 Volume
+1.69% +0.86% +4.57% +5.44% -5.93% Change
More quotes
Financials ($)
Sales 2017 131 M
EBIT 2017 -76,9 M
Net income 2017 -85,1 M
Debt 2017 -
Yield 2017 -
Sales 2018 131 M
EBIT 2018 -74,5 M
Net income 2018 -79,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 14,0x
Capi. / Sales2018 14,0x
Capitalization 1 832 M
More Financials
Company
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products.It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma.It operates through... 
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Latest news on SPECTRUM PHARMACEUTICALS,
11/17 SPECTRUM PHARMACEUTICALS, INC. : Today’s Research Reports on Trending Tickers: S..
11/16 CASI PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results
11/08 SPECTRUM PHARMACEUTICALS, INC. : Stonegate Capital Partners Updates Coverage on ..
11/08 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Jefferies 2017 Lon..
11/02 SPECTRUM PHARMACEUTICALS : Pharma reports 3Q loss
11/02 SPECTRUM PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
11/02 SPECTRUM PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results and Pipe..
11/02 SPECTRUM PHARMACEUTICALS, INC. : to Host Earnings Call
10/31 SPECTRUM PHARMACEUTICALS : Announces Initiation of a Multicenter Phase 2 Trial o..
10/30 SPECTRUM PHARMACEUTICALS : Announces Initiation of a Multicenter Phase 2 Trial o..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/02 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q3 2017 Results - Ea..
11/02 Spectrum Pharmaceuticals beats by $0.13, beats on revenue
11/01 Notable earnings after Thursday?s close
10/30 Spectrum Pharmaceuticals initiates Phase 2 trial of Poziotinib in certain NSC..
10/26 SIERRA ONCOLOGY : Significant Potential Upside In 2018
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Technical analysis trends SPECTRUM PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 28,7 $
Spread / Average Target 47%
EPS Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph W. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Luigi Lenaz Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICALS, INC.340.18%1 832
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.52%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538